3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gastrointestinal
1
Conditions
Pancreatic Neoplasms
4
Ovarian Neoplasms
4
Neoplasm Metastasis
4
Colorectal Neoplasms
4
Sarcoma
3
Sarcoma, Ewing
2
Insulin-Like Growth Factor I, Resistance To
2
Carcinoma, Non-Small-Cell Lung
2
Carcinoid Tumor
2
Breast Neoplasms
2
Small Cell Lung Carcinoma
1
Rhabdomyosarcoma, Embryonal
1
Rhabdomyosarcoma, Alveolar
1
Rhabdomyosarcoma
1
Recurrence
1
Rectal Neoplasms
1
Pleural Effusion, Malignant
1
Neuroendocrine Tumors
1
Neoplasms
1
Lymphoma
1
Lung Neoplasms
1
Jaundice
1
Gastrointestinal Neoplasms
1
Endocrine Gland Neoplasms
1
Colonic Neoplasms
1
Adenoma, Islet Cell
1
Adenocarcinoma
1
Interventions
Gemcitabine
4
Albumin-Bound Paclitaxel
3
130-nm albumin-bound paclitaxel
3
selpercatinib
2
tariquidar
1
pralsetinib
1
napabucasin
1
ganitumab
1
Irinotecan
1
Denosumab
1
Cisplatin
1
Capecitabine
1
Ascorbic Acid
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Has results
×
Endocrine Gland Neoplasms
×
ganitumab
×
Clear all
NCT01231347
2024-07-16
GAMMA
NantCell, Inc.
Phase 3
Completed
800 enrolled
11 charts